Welcome to our new brand!

Our new brand represents our passion and dedication to innovation, we utilize the latest technology and cutting-edge techniques to discover and advance ground breaking biologics to the clinic, whether this is our own pipeline or that of our partners. This video introduces our new brand across all our sites.

In Gdansk, we provide process development and GMP production of clinical and medium-scale commercial materials, supported by QC, QA and project management functions.

Quality is at the heart of Polpharma Biologics commitment to delivering safe and effective medicines to patients.

Located in Poland’s capital, Warsaw, and built to serve the growing global demand for biopharmaceuticals is our commercial-scale GMP production facility for drug substance. It is one of the largest and newest facilities of its kind in Europe.

Whether it’s helping our partners accelerate their programs, developing biosimilars to improve patients access or discovering new and innovative medicines to add to our portfolio, all our staff are motivated by the same passion, getting safe and effective medicines to patients.

Early discovery, development and optimization of novel therapeutics at Polpharma Biologics

You will have the opportunity to contribute to modern biotechnology using the latest equipment and most advanced technologies available. Our state-of-the-art biopharmaceutical R&D and manufacturing center in Gdansk is one of the most modern biotechnology centers in Europe, complemented by our new commercial manufacturing facility in Duchnice (near Warsaw), fully operational in 2021 and our early stage research site in Utrecht, Netherlands.

We offer fully integrated biopharmaceutical solutions for microbial products. From tech transfer to clinical supply including drug substance and drug product development and manufacturing for preclinical, clinical and commercial.

Located in the Utrecht Science Park, a hub for education, research, entrepreneurship and healthcare. The state-of-the-art facility focuses on the development of production cell lines for monoclonal antibodies (mAbs) and other proteins (including laboratory scale processes), as well as the generation of New Biological Entities (NBEs).

Our proprietary CHOBC® expression platform allows rapid generation of high-quality cell lines with a completely animal component-free (ACF) process. High-throughput technologies are deployed to increase productivity and achieve the highest titers possible, while minimizing undesired species.